Yadanzigan (YDZG), a natural product from Brucea javanica and a specific NLRP3 inhibitor, attenuates the NF-κB pathway and reactive oxygen species generation in mitochondria, while enhancing TRIM31, which has anti-inflammatory effects and prevents lps-induced acute lung injury.

Yadanzigan (20–80 μM; 24 h) significantly inhibited LPS (1 μg/mL) + ATP (5 mM)–induced NLRP3 inflammasome activation in RAW264.7, J774A.1, and THP-1 macrophages, reducing caspase-1 and IL-1β expression/secretion, enhancing TRIM31 expression, and suppressing mitochondrial ROS production[1].

In LPS-induced acute lung injury (ALI) mouse models, intravenous administration of Yadanzigan (5 or 10 mg/kg) significantly reduced NLRP3 and caspase-1 expression in lung tissues, alleviated histopathological damage, lowered leukocyte infiltration and inflammatory cytokines (IL-1β, TNF-α, IL-6), and improved survival[1].